Recent Discoveries of Diagnostic, Prognostic and Predictive Biomarkers for Pancreatic Cancer

Andrii Khomiak 1, Marius Brunner 2, Maximilian Kordes 3,4, Stina Lindblad 5, Rainer Christoph Miksch 6, Daniel Öhlund 5,* and Ivonne Regel 7,*

1 Shalimov National Institute of Surgery and Transplantology, 03058 Kyiv, Ukraine; kh.ndrew@gmail.com
2 Department of Gastroenterology, Endocrinology and Gastrointestinal Oncology, University Medical Center, 37075 Goettingen, Germany; marius.brunner@med.uni-goettingen.de
3 Department of Upper Abdominal Diseases, Karolinska University Hospital, 14186 Stockholm, Sweden; maximilian.kordes@ki.se
4 Department of Clinical Science, Intervention and Technology (CLINTEC), Karolinska Institutet, 17177 Stockholm, Sweden
5 Department of Radiation Sciences, Sweden and Wallenberg Centre for Molecular Medicine, Umeå University, 90187 Umeå, Sweden; stina.lindblad@umu.se
6 Department of General, Visceral and Transplantation Surgery, University Hospital, LMU Munich, 81377 Munich, Germany; rainer.miksch@med.uni-muenchen.de
7 Department of Medicine II, University Hospital, LMU Munich, 81377 Munich, Germany
* Correspondence: daniel.ohlund@umu.se (D.Ö.); ivonne.regel@med.uni-muenchen.de (I.R.);
Tel.: +46-90-785-17-27 (D.Ö.); +49-89-4400-73178 (I.R.)

Received: 8 October 2020; Accepted: 28 October 2020; Published: 2 November 2020

Simple Summary: Biomarkers for cancer diagnosis, prognosis and prediction are important tools and an urgent need in precision medicine for pancreatic cancer. In recent years, many experimental and clinical studies aimed at identifying new biomarkers for pancreatic ductal adenocarcinoma. In the review, we summarized current investigations on using novel protein markers, cell-free DNA, metabolome compounds, immune and stroma signatures and microbiome compositions as biomarkers for pancreatic cancer. Our comprehensive overview shows that although there are new promising biomarkers, CA 19-9 remains currently the only regularly used and validated biomarker for pancreatic cancer in clinical routine.

Abstract: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease with a dismal prognosis that is frequently diagnosed at an advanced stage. Although less common than other malignant diseases, it currently ranks as the fourth most common cause of cancer-related death in the European Union with a five-year survival rate of below 9%. Surgical resection, followed by adjuvant chemotherapy, remains the only potentially curative treatment but only a minority of patients is diagnosed with locally resectable, non-metastatic disease. Patients with advanced disease are treated with chemotherapy but high rates of treatment resistance and unfavorable side-effect profiles of some of the used regimens remain major challenges. Biomarkers reflect pathophysiological or physiological processes linked to a disease and can be used as diagnostic, prognostic and predictive tools. Thus, accurate biomarkers can allow for better patient stratification and guide therapy choices. Currently, the only broadly used biomarker for PDAC, CA 19-9, has multiple limitations and the need for novel biomarkers is urgent. In this review, we highlight the current situation, recent discoveries and developments in the field of biomarkers of PDAC and their potential clinical applications.

Keywords: pancreatic ductal adenocarcinoma; pancreatic cancer; protein biomarkers; microbiome biomarkers; metabolome biomarkers; DNA biomarkers; immune biomarkers
1. Introduction

Across patients with different types of malignant tumors, the stage at diagnosis, prognosis and success rates of anti-cancer treatment vary widely [1]. These disparities correspond to the complex nature of cellular, inter-cellular and organ-specific mechanisms that drive tumorigenesis. Biomarkers reflecting changes on either of these levels can be objectively measured to detect malignant and other diseases, to monitor their course and to select treatment strategies [2]. Pancreatic ductal adenocarcinoma (PDAC) is a highly malignant tumor of the exocrine pancreas with a poor prognosis. Although less common than other malignant diseases, it currently ranks as the fourth most common cause of cancer-related death in the European Union [1]. In four out of five cases, PDAC is diagnosed in a locally advanced or metastatic stage when it is not amenable to surgery [3]. The five-year survival rate among patients diagnosed with PDAC is below 9% [4,5]. Biomarkers can improve the care of cancer patients essentially in three different ways. Diagnostic markers can help to detect PDAC at an earlier and potentially curable stage. Prognostic markers can provide valuable information to patients and assist clinicians to adjust their treatment strategies according to the aggressiveness of the disease. Predictive markers can help to foresee how an individual patient might respond to a treatment and different treatment protocols can be selected based on a biological rationale. Because biomarkers reflect pathophysiological or physiological processes inherently linked to the disease there might also be a substantial overlap between the diagnostic, prognostic and predictive capacities of some markers. This review will focus on the current situation in the field of biomarkers of PDAC, highlight recent discoveries and discuss their potential in diagnostic, prognostic and predictive applications.

2. Clinical and Laboratory Features as Biomarkers

The term biomarker usually denotes a molecular marker, but even clinical parameters or other clinicopathological features might be relevant for the diagnosis, prognosis or prediction of treatment response. Several prognostic scores based on clinical features and routine laboratory values have been validated for PDAC [6]. The Glasgow Prognostic Score (GPS) incorporates serum C-reactive protein and albumin levels and has been shown to be a reliable independent prognostic factor in pancreatic, colorectal, gastro-esophageal, hepatocellular and other malignant tumors [7]. Moreover, the neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), the Prognostic Index (combination of C-reactive protein and white cell count) and Onodera’s Prognostic Nutritional Index have also been shown to be associated with cancer specific survival in patients with various cancers, including PDAC [8–10]. Using clinical data, such as age, tumor stage, alanine aminotransferase and albumin levels, several nomograms have been generated and validated to predict survival of patients with PDAC [11–15]. Notably, some of these nomograms have a global scope and can predict survival across all stages of PDAC [14], while others focus on specific stages, e.g., patients with locally advanced PDAC and aim to improve pre-operative treatment [15]. For guidance of chemotherapy regimens several nomograms have been developed. Nomograms are used to assess the efficacy of gemcitabine monotherapy, nab-paclitaxel/gemcitabine or FOLFIRINOX, which are the most widely used regimens for advanced PDAC [12,13,16]. In summary, GPS, NLR, PLR and several nomograms could discriminate patient sub-groups with different survival outcomes or guide therapy choices, but several issues, such as ill-defined cut-off values or a lack of validation, limit their use in clinical practice at the time.

3. Protein Biomarkers

To date, CA 19-9 is the only broadly accepted biomarker of PDAC. CA 19-9 is a sialyl-Lewis A tetrasaccharide, which about 10% of the population with a Lewis-negative genotype cannot express [5]. It has been extensively studied since the 1980s and it is currently the only diagnostic marker for PDAC approved by the U.S. Food and Drug Administration (FDA). In a meta-analysis including 26 studies with more than 2200 patients, the median sensitivity of elevated CA 19-9 to detect PDAC was 79% and the median specificity was 82% [17]. However, it is important to note that other malignant conditions, such as colorectal, lung and liver cancer or even benign diseases, such as cholestasis, pancreatitis or systemic lupus erythematosus, may cause
increased CA 19-9 levels [5]. In one of the largest multicenter datasets of more than 1900 pancreatic cancer patients, it was shown that the classification of CA19-9 levels has a prognostic value. Normal compared to increased CA 19-9 levels were associated with a hazard ratio (HR) for death between 0.68 (advanced stages III–IV) and 0.77 (stage I–II). Thus, high CA 19-9 levels have been implicated as an unfavorable prognostic marker that is linked to a short overall survival in patients with PDAC [18,19]. An important limitation of many studies investigating the prognostic value of CA 19-9 is their retrospective design and heterogeneous patient populations, which make it difficult to gauge the extent to which differences in survival are associated with different CA 19-9 levels. Notably, analyses of some prospective clinical trials have shown an association of CA 19-9 with survival in some cases, while there has not been any significant association in other trials. Therefore, some investigations postulate that CA 19-9 kinetics rather than baseline level correlate with overall survival [20]. A potential explanation for these disparate observations is the substantial variations of threshold values of CA 19-9 across different studies and that there is no universally accepted definition of a decrease of CA 19-9 as a proxy of tumor response. Thus, CA 19-9 needs to be interpreted with caution and in the clinical context of individual cases. Nevertheless, there is a large body of evidence that the CA 19-9 response to chemotherapy correlates with treatment outcomes and overall survival [21].

In addition to CA 19-9, the diagnostic or prognostic utility of several other carbohydrate antigens has been tested. Carcinoembryonic antigen (CEA) is widely used as a marker in different tumor entities and increased levels of CEA have been reported in more than 60% of PDAC patients [22]. Although the combination of CEA with CA 19-9 might improve the specificity of a diagnostic PDAC test, the sensitivity was shown to be poorer than for CA 19-9 alone [23]. CA 125 is an antigenic determinant on a high–molecular-weight glycoprotein recognized by a monoclonal antibody (OC 125), which was originally raised against an epithelial ovarian carcinoma cell line. CA 125 is a tumor marker in different types of cancers, such as ovarian, breast and lung neoplasms [24]. Its utility was also confirmed for the diagnosis of PDAC with slightly less sensitivity than CA 19-9 [25,26]. When used in combination with CA 19-9, CA 125 resulted in an improved specificity and could even yield clinically meaningful sensitivity for previously undiagnosed cases of PDAC [23,27]. Other carbohydrate markers, such as CA 50, CA 72-4 and CA 242, have been extensively studied in PDAC patients [28–31]. Although they exhibited less sensitivity than CA 19-9 for the diagnosis of PDAC, some studies reported improved specificity (Table 1). A large variety of combinations of carbohydrate markers was proposed to improve both specificity and sensitivity of the test [28,30,32]. Still, neither single carbohydrate marker tests, nor a combination of carbohydrate antigens are currently used in clinical practice, possibly due to a lack of standardization and absence of validation on larger cohorts.

Table 1. Summary of diagnostic sensitivity and specificity of carbohydrate biomarkers for Pancreatic ductal adenocarcinoma (PDAC).

| Biomarker, Serum | Reference | Sensitivity | Specificity | n of Patients |
|------------------|-----------|-------------|-------------|---------------|
| CA 19-9          | [33]      | 81          | 90          | 1040 *        |
|                  | [28]      | 75.5        | 77.6        | 3497 *        |
|                  | [17]      | 79          | 82          | 2283 *        |
|                  | [34]      | 81          | 81          | 3125 *        |
| CEA              | [35]      | 39          | 91          | 123           |
|                  | [28]      | 39.5        | 81.3        | 3497 *        |
|                  | [32]      | 45          | 75          | 68            |
| CA 125           | [36]      | 66.8        | 83.3        | 110           |
|                  | [35]      | 57          | 78          | 123           |
| CA 50            | [37]      | 84          | 85          | 200           |
|                  | [29]      | 46.3        | 90.9        | 112           |
|                  | [31]      | 82          | 78          | 129           |
| CA 72-4          | [31]      | 63.4        | 75.2        | 129           |
| CA 242           | [26]      | 67.8        | 83          | 3497 *        |
|                  | [31]      | 82          | 78          | 129           |
|                  | [38]      | 80          | 76          | 68            |

* meta-analysis.
In addition to carbohydrate antigens, several other proteins have been studied as PDAC serum markers. The macrophage inhibitory cytokine 1 (MIC-1) is a distant member of the transforming growth factor β superfamily and was originally found in colorectal, breast and prostate cancer [39–41]. Koopmann et al. measured serum MIC-1 levels of 80 patients with PDAC, 30 patients with ampullary cancer or cholangiocarcinoma, 42 patients with benign pancreatic tumors, 76 patients with chronic pancreatitis (CP) and 97 healthy subjects [42]. Serum MIC-1 levels were significantly higher in patients with PDAC and in patients with ampullary cancer or cholangiocarcinoma than in patients with benign pancreatic neoplasms, CP or in healthy controls. These differences were comparable to the CA 19-9 levels across groups [42]. Moreover, MIC-1 could differentiate patients with early-stage resectable PDAC significantly better from healthy individuals than CA 19-9 [43]. Moreover, Mucin glycoproteins, among them Mucin 1 (MUC1), are highly expressed in pancreatic cancer and detectable with monoclonal antibodies, such as PAM4 (clivatuzumab), that are reactive to MUC1 [44]. Using pancreatic cancer and pancreatitis specimens, the overall sensitivity and specificity of PAM4 to detect PDAC were 77% and 95%, respectively, with a Receiver Operating Characteristic (ROC) area under the curve (AUC) of 0.89. In this study, the accuracy of the PAM4 immunoassay assay was significantly better than that of CA19-9 [45].

PDAC is characterized by a dense fibrotic stroma that surrounds the cancer cells. During tumor progression, the collagen-rich stroma is modulated and rearranged to support the expansion of cancer cells. This is a dynamic process orchestrated by cancer cells and cancer-associated fibroblasts (CAFs), where fragments from collagens and other extracellular matrix (ECM) components of the stroma are spread to the circulation [46–48]. Thus, Osteopontin (OPN) is a protein of the ECM, with a variety of functions in cell adhesion and migration, inflammatory reaction and apoptosis. OPN has been found to be upregulated in PDAC and was linked to invasiveness as well as metastatic growth of pancreatic cancer cells [49,50]. Elevated OPN discriminated pancreatic cancer patients from healthy individuals with a sensitivity of 80% and a specificity of 97%, but did not perform significantly different from CA 19-9 [51]. Another study confirmed that OPN could distinguish PDAC from CP and healthy controls, but ROC analysis showed that OPN failed to improve diagnostic capability over CA 19-9 with an AUC of 0.72 and 0.92, respectively [52]. Another prognostic biomarker of PDAC was uncovered in a recent study that demonstrated an association of specific collagen fragments with the outcome of PDAC patients. Matrix metalloprotease (MMP)-degraded type I collagen (C1M), type III collagen (C3M), type IV collagen (C4M) and a pro-peptide of type III collagen (PRO-C3) were measured in the serum of patients prior to administration of 5-fluorouracil-based therapy for advanced-staged PDAC. High levels of circulating collagen fragments were consistently associated with a shorter overall survival [53].

In addition to blood-circulating biomarkers, the expression of specific proteins in tumor tissue is associated with the prognosis of PDAC or response to specific therapies. The human equilibrative nucleoside transporter 1 (hENT1) is a predictive tissue marker for the response to gemcitabine treatment [54,55]. A systematic analysis of the association of high versus low hENT1 expression with overall survival in gemcitabine-treated patients revealed hazard ratios (HR) for death in the range of 0.26 to 0.51 [56]. Another clinically interesting protein is dihydropyrimidine dehydrogenase (DPD). This enzyme is involved in the catalyzation of the chemotherapeutic drug 5-fluorouracil (5-FU) used in several treatment regimens for pancreatic cancer [57,58]. The correlation between treatment response and the presence of hENT1 and DPD in pancreatic tumor cells has been studied in the population from the ESPAC-4 trial. They were able to correlate high levels of DPD to worse prognosis for patients treated with 5-FU and established it as a negative predictive factor [59]. Moreover, low expression of the leucine-rich repeat-containing G-protein-coupled receptor (LGR5) was previously associated with a shorter survival in gastrointestinal cancer [60,61]. LGR5 is expressed in the cytoplasm of PDAC cells and in the basolateral membrane of a subset of endocrine cells of the human pancreas [62]. Among 78 PDAC cases, the expression of LGR5 was significantly higher in low histological grade (G1–G2) and early clinical stage. Congruently, the median overall survival (OS) of patients with tumors...
with a high LGR5 expression was 36 months compared to a median OS of 17 months of patients with a low LGR5 expression [63]. Overall, CA19-9 remains the only reliable, validated marker for prognostic use in patients with PDAC despite several tumor and serum proteins with a similar efficacy that could be used as biomarkers in the future. Particularly promising are the combinations of different markers. Still, further studies are required to validate novel protein biomarkers and implement them in clinical practice.

4. DNA Biomarkers

Cell free DNA (cfDNA) consists of circulating double-stranded DNA molecules that can be found in blood plasma or serum. Although the origin of cfDNA is still under debate, there is evidence that DNA is released during normal cell metabolism or apoptosis or necrosis. While cfDNA can be also found in healthy individuals, cancer patients have a significant higher concentration of cfDNA in the blood [64]. However, a direct quantification measurement of the cfDNA in plasma or serum was unsuccessful for the diagnosis of cancer [65]. Still, detection of tumor-specific mutations and epigenetic alteration in cfDNA is a promising direction for diagnostic and prognostic “liquid biopsies” in patients with different kind of tumors, including PDAC [66]. Pancreatic cancer was one of the first malignant diseases, in which specific single nucleotide variants (SNV) mutations in the KRAS (Kirsten rat sarcoma viral oncogene homolog) gene were detected in cfDNA [67]. Mutations in KRAS stand out among the genetic aberrations of PDAC, because they are present in more than 85% of the cancer cases and the vast majority of these mutations cluster into only three different variants in exon 12; G12D, G12V and G12R [68–70]. KRAS mutations (KRASmut) occur early in PDAC development [71]. Their high conservation and frequency make them a genetic hallmark of PDAC, and thus, KRASmut a potential genomic biomarker. Tumor-derived cfDNA in the plasma of PDAC patients are a small fraction among all cfDNA derived from healthy cells with fragments mainly in the 185–200 bp range [72]. While KRAS mutations occur in the majority of PDAC, the more complex mutational changes affecting other genes and the spatial heterogeneity of PDAC can also be identified in cfDNA [73–77]. Similarly, copy number alterations of PDAC have been detected in cfDNA [78]. Unsurprisingly, cfDNA and especially mutant KRAS, has been suggested as a diagnostic tool for PDAC and there is a high concordance between SNV in cfDNA and mutations in matched tissue samples [79].

In a large retrospective dataset of 403 patients with resectable PDAC and healthy individuals, the sensitivity of KRAS mutations in cfDNA was found to be 30% with 1/182 false positive samples [80]. Similar findings were observed in another cohort of 437 patients with PDAC, 141 patients with CP and 394 healthy individuals, where the KRASmut detection frequency was 21.1% among pancreatic cancer patients and 4.3% and 3.7% in pancreatitis patients and healthy individuals, respectively [81]. The discrimination between non-malignant and pre-malignant pancreatic lesions, such as intraductal papillary mucinous neoplasia (IPMN), and manifested tumors was improved by combining KRAS and GNAS mutation analysis as the assay performed quite well at discriminating between IPMN and PDAC [82]. In the CancerSEEK project, the sensitivity of cfDNA analysis was improved up to 75% by the incorporation of protein markers with few limitations in early detection of localized diseases [83]. At least one further study supports the incorporation of the protein markers CA19-9 and THBS2 into cfDNA analysis [84]. Another approach to overcome the limitations of KRASmut alone might include the analysis of degraded DNA fragments [85]. In addition, by analyzing the methylation status of two genes, ADAMTS1 and BNC1, in cfDNA, a 94.8% sensitivity and 91.6% specificity was achieved, supporting other reports that methylation patterns of cfDNA are able to identify early stage cancer [86,87]. Nevertheless, for patients with advanced PDAC or patients undergoing tumor surgery, increased plasma levels of tumor-associated cfDNA have been correlated to poorer clinical outcomes across several studies (Table 2). The majority of these studies focused on the detection of KRAS codon 12 mutations and used digital PCR and occasionally other methods such as peptide-nucleic acid clamp PCR and panel sequencing [88–90]. The detection rate of KRASmut in cfDNA varies across studies in the range of 26–42% [82,91,92].
Table 2. Plasma cell free DNA (cfDNA) and prognosis among patients with PDAC.

| Year     | Study Type         | Stage                      | Patients | Marker                              | Measure                                           | HR (95% CI for Death)               | Ref |
|----------|--------------------|----------------------------|----------|-------------------------------------|--------------------------------------------------|-------------------------------------|-----|
| 2019     | Prospective cohort | Localized and LAPC         | 194      | KRAS mutations                      | Presence of \(K\text{RAS}^{\text{mut}}\) cfDNA MAF 35% | 2.8 (1.4–5.7) *  
3.46 (1.4–8.5) * | [93] |
| 2017     | Retrospective cohort | Metastatic PDAC            | 188      | KRAS codon 12 and ERBB2 mutations   | Presence of \(K\text{RAS}^{\text{mut}}/\text{ERBB2}^{\text{mut}}\) cfDNA | Associated with a trend towards shorter OS | [94] |
| 2017     | Prospective cohort | Advanced PDAC              | 27       | KRAS MAF kinetics                   | KRAS MAF stability/decrease vs. increase mOS 6.5 vs. 11.5 months  
\((p = 0.009)\) | [95] |
| 2015     | Prospective cohort | Mixed localized and advanced PDAC | 31       | KRAS codon 12 mutations             | Presence of \(K\text{RAS}^{\text{mut}}\) cfDNA is associated with shorter OS  
12.2 (3.3–45.1) * | [91] |
| 2016     | Prospective cohort | Resectable PDAC            | 105      | KRAS codon 12 mutations             | Presence of \(K\text{RAS}^{\text{mut}}\) cfDNA  
3.2 (1.8–5.4) * | [92] |
| 2018     | Prospective cohort | Mixed localized and advanced PDAC | 106      | KRAS codon 12/13 mutations          | KRAS MAF > 0.415  
1.73 (0.95–3.14) * | [88] |
| 2018     | Prospective cohort | Advanced PDAC              | 54       | KRAS mutations                      | KRAS\text{mut} concentration Decrease in \(K\text{RAS}^{\text{mut}}\) correlates with response | [96] |
| 2018     | Prospective cohort | Advanced PDAC              | 61       | Total cfDNA                         | cfDNA \leq 167 bp above median plasma level  
2.24 (1.09–4.59) * | [97] |
| 2019     | Prospective cohort | LAPC and metastatic PDAC   | 55       | Copy numbers and KRAS mutations    | CAN †  
KRAS copy number-KRAS\text{mut} at baseline  
7.09 (3.19–15.78)  
10.94 (3.85–31.08)  
3.46 (1.76–6.77) | [98] |
| 2018     | Retrospective cohort | Resectable PDAC            | 45       | KRAS codon 12 mutations             | Presence of post-operative \(K\text{RAS}^{\text{mut}}\) cfDNA  
2.92 (1.11–5.62) | [99] |
| 2018     | Prospective cohort | Metastatic PDAC            | 17       | KRAS mutations                      | Detectable vs. no detectable \(K\text{RAS}^{\text{mut}}\) cfDNA mOS 8 vs. 37.5 months  
\((p < 0.004)\) | [100] |
| 2017     | Prospective cohort | Mixed localized and advanced PDAC | 104      | KRAS codon 12 mutations             | Detectable vs. no detectable \(K\text{RAS}^{\text{mut}}\) cfDNA KRAS MAF tertiles  
1.99 (1.3–3.5) *  
mos 18.9 vs. 7.8 vs. 4.9 months  
\((p < 0.001)\) | [101] |
| 2015     | Retrospective cohort | Mixed localized and advanced PDAC | 127      | KRAS codon 12 mutations and KRAS mutations concentrations | Detectable \(K\text{RAS}^{\text{mut}}\) cfDNA concentration > 62 ng/mL  
0.8 (0.48–1.3) ‡  
2.8 (1.8–4.6) | [38] |
| 2019     | Prospective cohort | Metastatic PDAC            | 58       | Custom NGS panel                    | MAF (per 1%)  
Detectable mutated cfDNA  
1.05 (1.01–1.09) *  
2.16 (1.21–3.85) ‡ | [69] |
| 2016     | Prospective cohort | Advanced PDAC              | 14       | KRAS codon 12 mutations             | Detectable \(K\text{RAS}^{\text{mut}}\)  
5.86 (p = 0.099) | [90] |
| 2019     | Prospective cohort | Advanced PDAC              | 38       | Custom NGS panel                    | Pre-treatment/follow-up MAF Not applicable | [102] |

* multivariate COX analysis; † copy number alterations; ‡ univariate Cox model; CNA, copy number alterations; MAF, mutant allele frequency; NGS, next-generation sequencing.
In a small series of patients undergoing chemotherapy, the level of KRAS\textsuperscript{mut} in cfDNA correlated also with the radiological tumor response or disease progression [94]. In a cohort of patients, who underwent resection of a localized PDAC, the presence of KRAS\textsuperscript{mut} cfDNA was detected in the plasma of 22/51 patients (43%) at the time of diagnosis. Using cfDNA to follow disease progression, KRAS mutations were detected as early as 3.1 months after surgery, compared to 9.6 months using standard CT. An early relapse of KRAS\textsuperscript{mut} in cfDNA predicted a clinical relapse and was associated with poor survival [103].

DNA hypermethylation of promoter regions is a well-known mechanism for the inactivation of tumor suppressor genes associated with carcinogenesis [104]. It has been previously shown that DNA hypermethylation has a prognostic value and may be used as an independent predictor of survival in different types of cancer [105–107]. Henriksen et al. examined the correlation between hypermethylated genes in plasma-derived cfDNA and survival of patients with PDAC [108]. Methylation-specific PCR of 28 genes was performed in a cohort of 95 patients with pancreatic cancer. Patients with more than 10 hypermethylated genes were found to have a HR for death of 2.03 (95% CI; 1.15–3.57) compared to patients with fewer hypermethylated genes. The authors have designed three prediction models based on cfDNA hypermethylation, which stratify PDAC patients into risk groups according to survival and have the potential to provide additional information as prognostic biomarkers [108]. Methylation profiling analysis in leukocyte DNA has also been shown to discriminate cancer patients from non-cancer controls, an approach that was pioneered in small-cell lung cancer [109].

Measuring methylation levels at 1505 CpG sites in treatment-naive leukocyte DNA from 132 PDAC patients and 60 healthy controls, Pedersen et al. could derive a prediction model that consisted of five CpG sites (IL10\_P348, LCN2\_P86, ZAP70\_P220, AIM2\_P624 and TAL1\_P817) to discriminate PDAC patients from controls. Moreover, one CpG site alone, LCN2\_P86, could differentiate patients with localized, resectable tumors from healthy individuals [110]. These data suggest that most of the early PDAC cases could be diagnosed non-invasively using diagnostic tests based on a few specific genetic alterations. Prognostic and predictive models based on liquid biopsies may also allow for better stratification of patients according to survival and tailor future therapy regimens.

5. Metabolomic Biomarkers

Analyzing the metabolome is a novel approach for the detection of cancer signatures, although there are currently no routinely used metabolic markers in clinical practice for diagnosis, prognosis assessment or prediction of the response to chemotherapy. There is, however, an increasing number of studies that show differences between metabolic profiles of PDAC patients, patients with other conditions or healthy controls [111–114]. In a case-control study, Mayerle et al. investigated the metabolic profile of blood samples from 914 patients with PDAC, CP, liver cirrhosis, healthy and non-pancreatic disease controls. The authors identified a biomarker signature (nine metabolites and additionally CA 19-9) that reliably distinguished PDAC from CP with a negative predictive value for cancer of 99.9% (95% CI 99.7–99.9%) [112]. In another study of 106 patients who underwent surgery for PDAC, tissue specimens were analyzed to find metabolic biomarkers associated with long-term survival, using metabolomics analysis. Network analysis revealed higher levels of glucose, ascorbate and taurine to be correlated with long-term survivorship. At the same time, long-time survivors tended to have decreased levels of choline, ethanolamine, glycerophosphocholine, phenylalanine, tyrosine, aspartate, threonine, succinate, glycerol, lactate, glycine, glutamate, glutamine and creatine. Among these metabolites, the level of ethanolamine had the highest accuracy to distinguishing long-term from short-term survivors. The AUC was 0.86 ± 0.1, with a sensitivity and specificity of 77.8% and 75%, respectively [115]. Another study analyzed the metabolomic profiles of tumor tissues from 25 patients, who underwent curative resection and adjuvant gemcitabine-based therapy. Elevated lactic acid levels were found in the tumors of patients with poor clinical outcomes after gemcitabine treatment. In contrast, patients with low levels of lactic acid and higher protein expression of hENT1 were found to have a significantly longer survival time than all other groups [116]. A general weakness with metabolomic studies, especially retrospective
ones, is that there are many aspects that need to be considered when comparing the results. The collected sample material, the sample preparation, the analytical platform and interpretations can influence the outcome. There is a need for further standardizations and validation of candidate metabolic signatures, preferably through studies with a robust design [117]. Although there is a need for further standardizations and validation of candidate metabolic signatures, metabolomics is a promising approach to provide new useful diagnostic, prognostic or predictive markers for PDAC patients.

6. Immune and Stroma Biomarkers

Pancreatic cancer is traditionally considered immune-cold neoplasm employing a great number of mechanisms for immune evasion. It possesses a complex tumor microenvironment (TME), which enables PDAC to evade the host immune system and explains low effectiveness of chemo-, radio- and novel immunotherapeutic approaches [118,119]. As been already shown in a variety of cancer types, a better understanding of the immune landscape could provide new rational targets for therapy and allow for better prognostic stratification than conventional staging systems [120–124].

The tumor microenvironment (TME) of pancreatic cancer consists of stromal and cellular compartments, which are both linked to prognosis and survival of patients. PDAC has a unique and abundant stromal component, comprising up to 90% of the tumor volume. While cellular infiltrates were originally considered to play a primary role in TME of PDAC, it has been recently proved that the stromal compartment is not a silent bystander. Pancreatic stellate cells (PSC) are considered primarily responsible for the synthesis of desmoplastic stroma. Their interaction with PDAC cells and effects on tumor microcirculation support tumor growth, metastatic spread and chemoresistance [124–128]. Several subtypes of pancreatic stroma were identified and associated with patients’ prognosis. Erkan et al. previously introduced the activated stroma index [129]. Furthermore, Knudsen et al. investigated in their study a cohort of 109 PDAC cases using histologic analysis and immunostaining to evaluate stromal characteristics of the tumor. The study identified three distinct stromal phenotypes based on the number of PSCs, presence of mature collagen fibers and loose extracellular matrix: immature, intermediate and mature. These phenotypes were significantly associated with survival times with immature subtype yielding shorter OS [130]. In the study of Moffitt et al., they utilized nonnegative matrix factorization to identify two different prognostic stromal subtypes, which were defined as “active” and “normal.” The active stroma subtype was correlated with a worse median survival of 15 month and a one-year survival rate of 60%, while patients with a normal stroma had a median survival time of 24 months and a one-year survival rate of 82% [131].

Deactivation of the tumor stroma has a significant impact on PDAC biology and therapeutic resistance [121]. Modulating the stroma in PDAC may be a tool to improve the effect of therapy. Neesse et al. could show that SPARC ablation reduces the collagen-rich microenvironment in murine models [132]. Furthermore, therapeutic treatments targeting the stroma aim to change its composition and decrease chemoresistance in PDAC patients. In a study by Gorchs et al., the authors showed that vitamin D3 analogues, that inhibit CAF proliferation and migration, appear to have dual functions in the context that calcipotriol reduces the tumor supportive activity of CAFs but at the same time reduces T cell effector functions, which could have important clinical implications [133]. In a study by Olive et al., an inhibitor of the hedgehog signaling pathway was shown to deplete the fibrotic stroma, and enhance chemotherapy delivery to cancer cells in a mouse model of PDAC [134], but these findings could not be repeated in a human setting. In contrary, follow up studies have shown that inhibition of the hedgehog pathway [135], or depletion of alpha-smooth muscle actin expressing CAFs [136], both leads to a depletion of the tumor stroma, but also to a more aggressive disease and reduced survival in mouse models of PDAC. This highlights the complexity of the tumor stroma, in particular for CAFs, and indicates that some stromal elements within the stroma instead restrain tumor progression. Recently, is has become clear that functionally distinct subtypes of CAFs are present in the PDAC stroma, such as myofibroblastic CAFs (myCAFs), inflammatory CAFs (iCAFs) [137] and antigen presenting CAFs (apCAFs) [138], all with potential different roles in the pathophysiology of
the disease (Figure 1). Altogether, this indicates that a future therapeutic strategy aiming at depleting the tumor stroma and/or CAFs has to target specific components of the stroma, and not the stroma in general, since this also might eliminate elements with tumor restraining functions. This also shows the great need of biomarkers that correctly can reflect the balance between the tumor restraining and tumor promoting elements of the stroma.

Figure 1. Immune infiltrates of pancreatic ductal adenocarcinoma form an immune suppressive environment. Anti-tumor immunity is suppressed through T-cell apoptosis, inhibition of cytotoxic T-cell recruitment and reduced secretion of pro-inflammatory cytokines, such as IL-4 and IL-5. PD-L1: Programmed death-ligand 1, Treg: regulatory T-cell, myCAFs: myofibroblastic cancer-associated fibroblast (CAF), iCAFs: inflammatory CAFs, apCAFs: antigen-presenting CAFs. Created with BioRender.com.

Tumor-infiltrating immune cells are considered to be one of the most important factors in the TME defining biological behavior of the tumor [139–141]. Multiple studies investigated intratumoral immune cell composition using immunohistochemistry and revealed an association with prognosis and survival of PDAC patients. The study by Tewari et al. has found a correlation between the presence of CD3 and CD8 positive lymphocytes in the tumor and the tumor differentiation grade. A higher presence of intratumoral and stromal CD3 and CD8 stained lymphocytes was associated with a lower tumor grade and better survival [142]. In a study by Ino et al., shorter survival was observed in the presence of high levels of tumor-infiltrating CD163+ or CD204+ M2 macrophages, neutrophils or a high density of regulatory T-cells (FoxP3+ cells). The same study found a higher level of tumor-infiltrating CD4+ T-cells, CD8+ T-cells or the ratio of HLA-DR+ and CD68+ M1 macrophages to pan-macrophages to convey a better prognosis and longer survival times for the patient [143]. Another study by Miksch et al. confirmed the importance of intra- and peritumoral immune cell infiltrates for patients’ prognosis and survival. The study found that high infiltration of CD3+, CD8+ and CD20+, which were predominantly observed in peritumoral “hot spots”, correlated significantly to OS and progression-free survival (PFS) in PDAC patients. A little number of immune cell infiltrates were found intratumorally, confirming a superb ability of PDAC to evade the host immune system. Importantly, the study did not find any association of patient survival times with the distance of the mentioned immune cell “hot spots” and tumor front [144]. Programmed death-1 ligand (PD-L1) has been suggested to play a crucial role in this immune system escape through negative regulation of T-cell function, since higher PD-L1 levels were inversely correlated with the quantity of tumor immune cell infiltrates [145]. Most attempts to apply immunotherapy regimens for the treatment of PDAC proved to be ineffective. Immunosuppressive tumor milieu and dense fibrotic stroma modulated by CAFs are thought to be responsible for the failure of most approaches (Figure 1). There are, however, a few promising
trials published. Adaptive T-cell transfer, pancreatic cancer vaccines, immune checkpoint inhibitors and co-stimulatory agents are the approaches currently under investigation for the treatment of pancreatic cancer [146–148]. Adaptive T-cell transfer is an approach with ex-vivo activation of host T-cells with subsequent reinfusion. Promising results were published on this strategy that was applied in hematologic malignancies, but efficacy of the approach for the treatment of solid neoplasms is yet to be determined [149–151]. Of high interest are results of a phase I trial, in which Beatty et al. investigated safety and efficacy of adoptive cell therapy with autologous mesothelin-specific chimeric antigen receptor T-cells in six patients with chemotherapy-refractory metastatic PDAC. Stable disease with progression-free survival times of 3.8 and 5.4 months was achieved in two patients. Total tumor metabolic active volume (MAV) on positron emission tomography was stable in three patients and decreased in one patient, who also had decreased activity of metastatic lesion in the liver [146].

Pancreatic cancer vaccines have gained a lot of attention recently. Mutated RAS peptide vaccine was found to be of clinical benefit in adjuvant setting [152,153]. In the study of Wedén et al. the rate of immune response is reported to be as high as 85% with 10-year survival of 20% in responders versus zero in a cohort of non-vaccinated patients [152]. Another study reports a peptide-specific immunity induced in 56% patients with median survival of 148 days vs. 61 days, in vaccinated and non-vaccinated patients, respectively [153]. Granulocyte-macrophage colony-stimulating factor-secreting factor-secreting tumor vaccine was found to be effective in adjuvant settings, when combined with chemoradiation, gemcitabine or Listeria vaccine that expresses mesothelin [154–156]. The latter combination of two vaccines demonstrated an improved OS of 6.1 vs. 3.9 months compared to single vaccine alone and was even granted FDA breakthrough designation [156]. Groeneveldt et al. highlighted the importance of preconditioning in PDAC. They showed results sensitizing the tumor microenvironment for subsequent CD3-bsAb therapy in combination with an oncolytic reovirus [157]. A limited number of studies have been completed on immune checkpoint inhibitors with disappointing results published both on CTLA-4 and PD-L1 inhibitors [147,148]. However, it has been hypothesized that PDAC with deficiency in DNA mismatch repair (MMR) has increased sensitivity to immune checkpoint blockade with anti-PD-1 antibodies. A recent study of Le et al. investigated the effects of PD-1 blockade using pembrolizumab in MMR-deficient tumors independently of the tissue of origin and included 86 patients with 12 different tumor types (including PDAC). Fifty-three percent of patients achieved radiological response, whereby a complete response was observed in 21% of patients. Response was durable with median progression-free and overall survival still not reached [152]. Rapid expansion of neoantigen-specific T-cell clones that were reactive to mutant neoepitopes, created by the multiple somatic mutations in cancers, were found in the tumor of responders. These data support the hypothesis that a large proportion of mutant neoantigens in MMR-deficient pancreatic cancer makes the tumor susceptible to immune checkpoint blockade [158].

In summary, stromal subtypes influence, together with inflammatory cytokines levels, the prognosis of the patients with PDAC. Stromal maturity as well as activation status are considered to be important prognostic features. A general weakness of studies investigating immune markers for prognostic or predictive implications is a retrospective design limiting their future clinical application. A very low number of studies show promising results for immunotherapy approaches in PDAC, in which a small subset of PDAC patients with MMR deficiency might benefit. These data show that the immune milieu of PDAC is very complex and requires combinatorial approaches for prognostic and predictive application and increasing efforts to develop future immunotherapy regimens. A better understanding of the mechanisms that regulate the PDAC immunosuppressive environment could reveal specific disease subtypes with enhanced prognostic significance and allow for additional targeted treatment approaches.

7. Microbiome Biomarkers

The correlation between the gut and oral microbiome and pancreatic cancer has become the center of attention recently and is discussed in detail in an excellent review from Picardo et al. [159].
Hence, many recent studies have focused on the tumor microbiome to discover prognostic factors for PDAC. If understood better, microbiome screening methods might be able to predict the risk of pancreatic cancer and, in the course of the disease, help to decide the best treatment options. The tumor microbiome in pancreatic cancer is strongly linked to both the oral and gut microbiome. Immunofluorescent-labeled bacteria given orally to mice were found in the tumor six to eight weeks later, maybe even providing a potential possibility to carry therapeutic agents into the tumor tissue \cite{158,160,161}. Prognostic relevance of the tumor microbiome was shown by Mitsuhashi et al., who demonstrated that tumors harboring fusobacterium species, which occurred in approximately 10% of cases, have a significantly poorer prognosis (HR 2.16, 95%-CI, 1.12–3.91), underlining a possible prognostic application after acquiring biopsies or surgery specimen \cite{162}. However, other studies have identified fusobacteria to be associated with a reduced PDAC risk, postulating that there might be a different role between oral fusobacteria and tumor fusobacteria \cite{163}. A correlation between the gut microbiome and the response to immunotherapy has been shown in other malignancies \cite{164,165}. In a recent publication, Riquelme et al. showed that the gut microbiome of long-term pancreatic cancer survivors was significantly more diverse than that of short-term survivors \cite{166–168}. Most strikingly, tumor-bearing mice, who underwent the transplantation of both oral and gut microbiomes, were found to survive significantly longer with the fecal transplant of long-term survivors, postulating a strong interaction between tumor biology and gut microbiome. Furthermore, Mendez et al. described that pancreatic cancer patients show a significantly elevated serum polyamine level as a consequence of microbial dysbiosis, which is known to be actively assimilated by the host and eventually utilized by rapidly dividing cells for proliferation being of importance in the process of tumorigenesis \cite{169}. The response to chemotherapy could also be linked to the tumor microbiome through intra-tumoral bacteria, which might contribute to drug resistance of PDAC. Of 113 human pancreatic cancer tissue samples that were tested, 86 (76%) were positive for bacteria, mainly Gammaproteobacteria, which was previously correlated to gemcitabine-resistance \cite{170}.

In summary, the data show that the tumor microbiome diversity has a powerful prognostic significance and can potentially modulate tumor sensitivity to gemcitabine. However, data from microbiome influence on PDAC outcome are still preliminary for establishing the microbiome as a solid biomarker. In addition, further studies have to be conducted to evaluate the role of fecal microbiota transplants as a possibility to increase chemotherapy sensitivity in PDAC patients.

8. Conclusions

Various new biomarkers for PDAC have emerged over the past decade, but none of these markers has been established in clinical routine. Our improved understanding of the tumor biology and microenvironment of PDAC increased the efforts on biomarker detection. Moreover, an increase in availability and reduction in cost for analytical methods, such as sequencing, supports a broad application of biomarker identification. However, several of these new approaches struggled to outperform CA 19-9, which is the only broadly used biomarker of PDAC for more than 20 years. A combination of markers or markers relying on panel or omics approaches to characterize disease-associated patterns, which overcome this limitation and implementation of new diagnostic, prognostic and predictive biomarkers for PDAC, could significantly improve the quality of care and ultimately survival of the pancreatic cancer patients.

Author Contributions: A.K., M.B., M.K., R.C.M., S.L., D.Ö. and I.R. designed the concept and wrote the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding: I.R. received funding from Deutsche Forschungsgemeinschaft, DFG RE3754/2-1, DFG RE3754/3-1 and Wilhelm Sander-Stiftung 2019.083.1. D.Ö. was supported by the Swedish Research Council (2017-01531), the Swedish Society of Medicine (SLS-786661 and SLS-890521), The Sjöberg Foundation, funds through Region Västerbotten (RV-930167 and VLL-832001), the Cancer Research Foundation in Northern Sweden (LP 20-2257 and LP 18-2202), the Knut and Alice Wallenberg Foundation and the Swedish Cancer Society (CAN 2017/332 and CAN 2017/827). M.K. received funding from Region Stockholm (20180661) and the Robert Lundberg Memorial Foundation (FS-2020:0004).
Acknowledgments: This review was initiated and supported by organizers of Pancreas 2000, an educational and research program designed for tomorrows pancreatologists, especially Matthias Löhr. This study was conducted as a project of the 9th Pancreas2000 education and research program funded by the Acibadem Mehmet Ali Aydinlar University, the Karolinska Institute and the European Pancreatic Club/EPC.

Conflicts of Interest: M.K.: Travel, Accommodations, Expenses: Molecular Health; Consultancy: Roche, Alligator Bioscience.

References
1. Ferlay, J.; Colombet, M.; Soerjomataram, I.; Dyba, T.; Randi, G.; Bettio, M.; Gavin, A.; Visser, O.; Bray, F. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. *Eur. J. Cancer* 2018, 103, 356–387. [CrossRef] [PubMed]
2. Atkinson, A.J.; Colburn, W.A.; DeGruttola, V.G.; DeMets, D.L.; Downing, G.J.; Hoth, D.F.; Oates, J.A.; Peck, C.C.; Schooley, R.T.; Spilker, B.A.; et al. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. *Clin. Pharm.* 2001, 69, 89–95.
3. Löhr, M. Is it possible to survive pancreatic cancer? *Nat. Clin. Pract. Gastroenterol. Hepatol.* 2006, 3, 236–237. [CrossRef]
4. Minicozzi, P.; Cassetti, T.; Vener, C.; Sant, M. Analysis of incidence, mortality and survival for pancreatic and biliary tract cancers across Europe, with assessment of influence of revised European age standardisation on estimates. *Cancer Epidemiol.* 2018, 55, 52–60. [CrossRef] [PubMed]
5. Rawla, P.; Sunkara, T.; Gaduputi, V. Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors. *World J. Oncol.* 2019, 10, 10–27. [CrossRef]
6. Ahmad, J.; Grimes, N.; Farid, S.; Morris-Stiff, G. Inflammatory response related scoring systems in assessing the prognosis of patients with pancreatic ductal adenocarcinoma: A systematic review. *Hepatobiliary Pancreat. Dis. Int.* 2014, 13, 474–481. [CrossRef]
7. McMillan, D.C. The systemic inflammation-based Glasgow Prognostic Score: A decade of experience in patients with cancer. *Cancer Treat. Rev.* 2013, 39, 534–540. [CrossRef]
8. Proctor, M.J.; Morrison, D.S.; Talwar, D.; Balmer, S.M.; Fletcher, C.D.; O’Reilly, D.S.J.; Foulis, A.K.; Horgan, P.G.; Mcmillan, D.C. A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study. *Eur. J. Cancer* 2011, 47, 2633–2641. [CrossRef] [PubMed]
9. Yang, J.J.; Hu, Z.G.; Shi, W.X.; Deng, T.; He, S.Q.; Yuan, S.G. Prognostic significance of neutrophil to lymphocyte ratio in pancreatic cancer: A meta-analysis. *World J. Gastroenterol.* 2015, 21, 2807–2815. [CrossRef] [PubMed]
10. Zhou, Y.; Cheng, S.; Fathy, A.H.; Qian, H.; Zhao, Y. Prognostic value of platelet-to-lymphocyte ratio in pancreatic cancer: A comprehensive meta-analysis of 17 cohort studies. *Onco. Targets Ther.* 2018, 11, 1899–1908. [CrossRef] [PubMed]
11. Deng, Q.L.; Dong, S.; Wang, L.; Zhang, C.Y.; Ying, H.F.; Li, Z.S.; Shen, X.H.; Guo, Y.B.; Meng, Z.Q.; Yu, J.M.; et al. Development and Validation of a Nomogram for Predicting Survival in Patients with Advanced Pancreatic Ductal Adenocarcinoma. *Sci. Rep.* 2017, 7, 1–8. [CrossRef] [PubMed]
12. Fernández, A.; Salgado, M.; García, A.; Buxò, E.; Vera, R.; Adeva, J.; Jiménez-Fonseca, P.; Quintero, G.; Llorca, C.; Cañabate, M.; et al. Prognostic factors for survival with nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer in real-life practice: The ANICE-PaC study. *BMC Cancer* 2018, 18, 1185. [CrossRef] [PubMed]
13. Hamada, T.; Nakai, Y.; Yasunaga, H.; Isayama, H.; Matsu, H.; Takahara, N.; Sasaki, T.; Takagi, K.; Watanabe, T.; Yagioka, H.; et al. Prognostic nomogram for nonresectable pancreatic cancer treated with gemcitabine-based chemotherapy. *Br. J. Cancer* 2014, 110, 1943–1949. [CrossRef]
14. Song, W.; Miao, D.L.; Chen, L. Nomogram for predicting survival in patients with pancreatic cancer. *OncoTargets Ther.* 2018, 11, 539–545. [CrossRef]
15. Vernerey, D.; Huguet, F.; Vienot, A.; Goldstein, D.; Paget-Bailly, S.; Van Laethem, J.L.; Glimelius, B.; Artru, P.; Moore, M.J.; André, T.; et al. Prognostic nomogram and score to predict overall survival in locally advanced untreated pancreatic cancer (PROLAP). *Br. J. Cancer* 2016, 115, 281–289. [CrossRef] [PubMed]
16. Fornaro, L.; Leone, F.; Vienot, A.; Casadei-Gardini, A.; Vivaldi, C.; Lièvre, A.; Lombardi, P.; De Luca, E.; Vernerey, D.; Sperti, E.; et al. Validated Nomogram Predicting 6-Month Survival in Pancreatic Cancer Patients Receiving First-Line 5-Fluorouracil, Oxaliplatin, and Irinotecan. *Clin. Colorectal Cancer* 2019, 18, e394–e401. [CrossRef] [PubMed]
17. Goonetilleke, K.S.; Siriwardena, A.K. Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. *Eur. J. Surg. Oncol.* 2007, 33, 266–270. [CrossRef] [PubMed]

18. Martin, L.K.; Wei, L.; Troli, E.; Bekaii-Saab, T. Elevated baseline CA19-9 levels correlate with adverse prognosis in patients with early- or advanced-stage pancreas cancer. *Med. Oncol.* 2012, 29, 3101–3107. [CrossRef]

19. Luo, G.; Jin, K.; Guo, M.; Cheng, H.; Liu, Z.; Xiao, Z.; Lu, Y.; Long, J.; Liu, L.; Xu, J.; et al. Patients with normal-range CA19-9 levels represent distinct subgroup of pancreatic cancer patients. *Oncol. Lett.* 2017, 13, 881–886. [CrossRef]

20. Tabernero, J.; Chiorean, E.G.; Infante, J.R.; Hingerani, S.R.; Ganju, V.; Weekes, C.; Scheithauer, W.; Ramanathan, R.K.; Goldstein, D.; Penenberg, D.N.; et al. Prognostic Factors of Survival in a Randomized Phase III Trial (MPACT) of Weekly nab- Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone in Patients With Metastatic Pancreatic Cancer. *Oncologist* 2015, 20, 143–150. [CrossRef]

21. Wasan, H.S.; Springett, G.M.; Chodkiewicz, C.; Wong, R.; Maurel, J.; Barone, C.; Rosbrook, B.; Ricart, A.D.; Kim, S.; Spano, J.P. CA 19-9 as a biomarker in advanced pancreatic cancer patients randomised to gemcitabine plus axitinib or gemcitabine alone. *Br. J. Cancer* 2009, 101, 1162–1167. [CrossRef] [PubMed]

22. Satake, K.; Chung, Y.S.; Yokomatsu, H.; Nakata, B.; Tanaka, H.; Sawada, T.; Nishiwaki, H.; Umemaya, K. A clinical evaluation of various tumor markers for the diagnosis of pancreatic cancer. *Int. J. Pancreatol.* 1990, 7, 25–36.

23. Meng, Q.; Shi, S.; Liang, C.; Liang, D.; Xu, W.; Ji, S.; Zhang, B.; Ni, Q.; Xu, J.; Yu, X. Diagnostic and prognostic value of carcinoembryonic antigen in pancreatic cancer: A systematic review and meta-analysis. *Onco Targets Ther.* 2017, 10, 4591–4598. [CrossRef]

24. Sjövall, K.; Nilsson, B.; Einhorn, N. The significance of serum CA 125 elevation in malignant and nonmalignant diseases. *Gynecol. Oncol.* 2002, 85, 175–178. [CrossRef]

25. Benini, L.; Cavallini, G.; Zordan, D.; Rizzotti, P.; Rigo, L.; Brocco, G.; Perobelli, L.; Zanchetta, M.; Pederzoli, P.; Scuro, L.A. A clinical evaluation of monoclonal (CA19-9, CA50, CA12-5) and polyclonal (CEA, TPA) antibody-defined antigens for the diagnosis of pancreatic cancer. *Pancreas* 1988, 3, 61–66. [CrossRef] [PubMed]

26. Gattani, A.M.; Mandeli, J.; Bruckner, H.W. Tumor markers in patients with pancreatic carcinoma. *Cancer* 1996, 78, 57–62. [CrossRef]

27. O’Brien, D.P.; Sandanayake, N.S.; Jenkinson, C.; Gentry-Maharaj, A.; Apostolidou, S.; Fourkala, E.O.; Camuzeaux, S.; Blyuss, O.; Gunu, R.; Dawny, A.; et al. Serum CA19-9 is significantly upregulated up to 2 years before diagnosis with pancreatic cancer: Implications for early disease detection. *Clin. Cancer Res.* 2015, 21, 622–631. [CrossRef] [PubMed]

28. Zhang, Y.; Yang, J.; Li, H.; Wu, Y.; Zhang, H.; Chen, W. Tumor markers CA19-9, CA242 and CEA in the diagnosis of pancreatic cancer: A meta-analysis. *Int. J. Clin. Exp. Med.* 2015, 8, 11683–11691.

29. Liao, Q.; Zhao, Y.-P.; Yang, Y.-C.; Li, L.-J.; Long, X.; Han, S.-M. Combined detection of serum tumor markers for differential diagnosis of solid lesions located at the pancreatic head. *Hepatobiliary Pancreat. Dis. Int.* 2007, 6, 641–645.

30. Wu, X.; Lu, X.H.; Xu, T.; Qian, J.M.; Zhao, P.; Guo, X.Z.; Yang, X.O.; Jiang, W.J. Evaluation of the diagnostic value of serum tumor markers, and fecal k-ras and p53 gene mutations for pancreatic cancer. *Clin. Cancer Res.* 2006, 7, 170–174. [CrossRef]

31. Jiang, X.T.; Tao, H.Q.; Zou, S.C. Detection of serum tumor markers in the diagnosis and treatment of patients with pancreatic cancer. *Hepatobiliary Pancreat. Dis. Int.* 2004, 3, 464–468. [PubMed]

32. Ni, X.G.; Bai, X.F.; Mao, Y.L.; Shao, Y.F.; Wu, J.X.; Shan, Y.; Wang, C.F.; Wang, J.; Tian, Y.T.; Liu, Q.; et al. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer. *Eur. J. Surg. Oncol.* 2005, 31, 164–169. [CrossRef]

33. Steinberg, W. The clinical utility of the CA 19-9 tumor-associated antigen. *Am. J. Gastroenterol.* 1990, 85, 350–355.

34. Su, S.B.; Qin, S.Y.; Chen, W.; Luo, W.; Jiang, H.X. Carbohydrate antigen 19-9 for differential diagnosis of pancreatic carcinoma and chronic pancreatitis. *World J. Gastroenterol.* 2015, 21, 4323–4333. [CrossRef]

35. Duraker, N.; Hot, S.; Polat, Y.; Höbek, A.; Gençler, N.; Urban, N. CEA, CA 19-9, and CA 125 in the differential diagnosis of benign and malignant pancreatic diseases with or without jaundice. *J. Surg. Oncol.* 2007, 95, 142–147. [CrossRef]

36. Ćwik, G.; Wallner, G.; Skoczylas, T.; Ciechański, A.; Zinkiewicz, K. Cancer antigens 19-9 and 125 in the differential diagnosis of pancreatic mass lesions. *Arch. Surg.* 2006, 141, 968–973. [CrossRef] [PubMed]
37. Kobayashi, T.; Kawa, S.; Tokoo, M.; Oguchi, H.; Kiyosawa, K.; Furuta, S.; Kanai, M.; Homma, T. Comparative study of CA-50 (time-resolved fluororimmunoassay), span-1, and CA19-9 in the diagnosis of pancreatic cancer. Scand. J. Gastroenterol. 1991, 26, 787–797. [CrossRef]

38. Singh, N.; Gupta, S.; Pandey, R.M.; Chauhan, S.S.; Saraya, A. High levels of cell-free circulating nucleic acids in pancreatic cancer are associated with vascular encasement, metastasis and poor survival. Cancer Investig. 2015, 33, 78–85. [CrossRef] [PubMed]

39. Bootcov, M.R.; Bauskin, A.R.; Valenzuela, S.M.; Moore, A.G.; Bansal, M.; He, X.Y.; Zhang, H.P.; Donnellan, M.; Mahler, S.; Pryor, K.; et al. MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-β superfamily. Proc. Natl. Acad. Sci. USA 1997, 94, 11514–11519. [CrossRef]

40. Welsh, J.B.; Sapinoso, L.M.; Kern, S.G.; Hampton, G.M.; Su, A.I.; Wang-Rodriguez, J.; Moskaluk, C.A.; Frierson, H.F. Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer Res. 2001, 61, 5974–5978.

41. Lee, D.H.; Yang, Y.; Lee, S.J.; Kim, K.Y.; Koo, T.H.; Shin, S.M.; Song, K.S.; Lee, Y.H.; Kim, Y.J.; Lee, J.J.; et al. Macrophage inhibitory cytokine-1 induces the invasiveness of gastric cancer cells by up-regulating the urokinase-type plasminogen activator system. Cancer Res. 2003, 63, 4648–4655.

42. Koopmann, J.; Buckhaults, P.; Brown, D.A.; Zahurak, M.L.; Sato, N.; Fukushima, N.; Sokoll, L.J.; Chan, D.W.; Yeo, C.J.; Hruban, R.H.; et al. Serum Macrophage Inhibitory Cytokine 1 as a Marker of Pancreatic and Other Periampullary Cancers. Clin. Cancer Res. 2004, 10, 2386–2392. [CrossRef]

43. Koopmann, J.; Rosenzweig, C.N.W.; Zhang, Z.; Canto, M.I.; Brown, D.A.; Hunter, M.; Yeo, C.; Chan, D.W.; Breit, S.N.; Goggins, M. Serum markers in patients with resectable pancreatic adenocarcinoma: Macrophage inhibitory cytokine 1 versus CA19-9. Clin. Cancer Res. 2006, 12, 442–446. [CrossRef] [PubMed]

44. Gold, D.V.; Lew, K.; Malinik, R.; Hernandez, M.; Cardillo, T. Characterization of monoclonal antibody PAM44 reactive with a pancreatic cancer mucin. Int. J. Cancer 1994, 57, 204–210. [CrossRef] [PubMed]

45. Gold, D.V.; Modrak, D.E.; Ying, Z.; Cardillo, T.M.; Sharkey, R.M.; Goldenberg, D.M. New MUC1 serum immunoassay differentiates pancreatic cancer from pancreatitis. J. Clin. Oncol. 2006, 24, 252–258. [CrossRef] [PubMed]

46. Öhlund, D.; Ardnor, B.; Öman, M.; Naredi, P.; Sund, M. Expression pattern and circulating levels of endostatin in patients with pancreas cancer. Int. J. Cancer 2008, 122, 2805–2810. [CrossRef]

47. Franklin, O.; Öhlund, D.; Lundin, C.; Öman, M.; Naredi, P.; Wang, W.; Sund, M. Combining conventional and stroma-derived tumour markers in pancreatic ductal adenocarcinoma. Cancer Biomark. 2015, 15, 1–10. [CrossRef] [PubMed]

48. Hlund, D.; Lundin, C.; Ardnor, B.; Man, M.; Naredi, P.; Sund, M. Type IV collagen is a tumour stroma-derived biomarker for pancreas cancer. Br. J. Cancer 2009, 101, 91–97. [CrossRef]

49. Zhivkova-Galunska, M.; Adwan, H.; Eyol, E.; Kleeff, J.; Kolb, A.; Bergmann, F.; Berger, M.R. Osteopontin but not osteonectin favors the metastatic growth of pancreatic cancer cell lines. Cancer Biol. 2010, 10, 54–64. [CrossRef]

50. Kolb, A.; Kleeff, J.; Guweidhi, A.; Esposito, I.; Giese, N.A.; Adwan, H.; Giese, T.; Büchler, M.W.; Berger, M.R.; Friess, H. Osteopontin influences the invasiveness of pancreatic cancer cells and is increased in neoplastic and inflammatory conditions. Cancer Biol. 2005, 4, 740–746. [CrossRef] [PubMed]

51. Koopmann, J.; Fedarko, N.S.; Jain, A.; Maitra, A.; Iacobuzio-Donahue, C.; Rahman, A.; Hruban, R.H.; Yeo, C.J.; Goggins, M. Evaluation of osteopontin as biomarker for pancreatic adenocarcinoma. Cancer Epidemiol. Biomark. Prev. 2004, 13, 487–491. [CrossRef]

52. Poruk, K.E.; Firpo, M.A.; Scaife, C.L.; Adler, D.G.; Emerson, L.L.; Boucher, K.M.; Mulvihill, S.J. Serum osteopontin and tissue inhibitor of metalloproteinase 1 as diagnostic and prognostic biomarkers for pancreatic adenocarcinoma. Pancreas 2013, 42, 193–197. [CrossRef]

53. Williamsen, N.; Ali, S.M.; Leitzel, K.; Drabick, J.J.; Yee, N.; Polimera, H.V.; Nagabhairu, V.; Krecko, L.; Ali, A.; Maddukuri, A.; et al. Collagen fragments quantified in serum as measures of desmoplasia associate with survival outcome in patients with advanced pancreatic cancer. Sci. Rep. 2019, 9, 19761. [CrossRef] [PubMed]

54. Greenhalf, W.; Ghaneh, P.; Neoptolemos, J.P.; Palmer, D.H.; Cox, T.F.; Lamb, R.E.; Garner, E.; Campbell, F.; MacKey, I.R.; Costello, E.; et al. Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial. J. Natl. Cancer Inst. 2014, 106, djt347. [CrossRef] [PubMed]

55. Borbath, I.; Verbrugghe, L.; Lai, R.; Gigot, J.F.; Humblet, Y.; Piessevaux, H.; Sempoux, C. Human equilibrative nucleoside transporter 1 (hENT1) expression is a potential predictive tool for response to gemcitabine in patients with advanced cholangiocarcinoma. Eur. J. Cancer 2012, 48, 990–996. [CrossRef]
56. Nordh, S.; Ansari, D.; Andersson, R. hENT1 expression is predictive of gemcitabine outcome in pancreatic cancer: A systematic review. *World J. Gastroenterol.* 2014, 20, 8482–8490. [CrossRef] [PubMed]

57. Longley, D.B.; Harkin, D.P.; Johnston, P.G. 5-Fluorouracil: Mechanisms of action and clinical strategies. *Nat. Rev. Cancer* 2003, 3, 330–338. [CrossRef]

58. Conroy, T.; Desseigne, F.; Ychou, M.; Bouché, O.; Guimbaud, R.; Bécouarn, Y.; Adenis, A.; Raoul, J.L.; Gourgou-Bourgade, S.; De La Fouillade, C.; et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. *N. Engl. J. Med.* 2011, 364, 1817–1825. [CrossRef]

59. Elander, N.O.; Aughton, K.; Ghanie, P.; Neoptolemos, J.P.; Palmer, D.H.; Cox, T.F.; Campbell, F.; Costello, E.; Halloran, C.M.; Mackey, J.R.; et al. Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer. *Br. J. Cancer* 2018, 118, 947–954. [CrossRef]

60. Simon, E.; Petke, D.; Böger, C.; Behrens, H.M.; Warneke, V.; Ebert, M.; Röcken, C. The spatial distribution of LGR5+ cells correlates with gastric cancer progression. *PloS ONE* 2012, 7, e35486. [CrossRef]

61. Becker, L.; Huang, Q.; Mashimo, H. Lgr5, an intestinal stem cell marker, is abnormally expressed in Barrett’s esophagus and esophageal adenocarcinoma. *Dis. Esophagus* 2010, 23, 168–174. [CrossRef] [PubMed]

62. Mizuno, N.; Yatabe, Y.; Hara, K.; Hijikata, S.; Imaoka, H.; Shimizu, Y.; Ko, S.B.H.; Yamao, K. Cytoplasmic expression of LGR5 in pancreatic adenocarcinoma. *Front. Physiol.* 2013, 4, 269. [CrossRef]

63. Kuraishi, Y.; Uehara, T.; Kobayashi, Y.; Nakajima, T.; Watanabe, T.; Shimizu, A.; Ota, H.; Tanaka, E. Correlation of clinicopathological features and leucine-rich repeat-containing G-protein-coupled receptor 5 expression in pancreatic ductal adenocarcinoma. *Pathol. Res. Pract.* 2019, 215, 152623. [CrossRef]

64. Jahr, S.; Hentze, H.; Englisch, S.; Hardt, D.; Fackelmayer, F.O.; Hesch, R.D.; Knippers, R. DNA fragments in the blood plasma of cancer patients: Quantitations and evidence for their origin from apoptotic and necrotic cells. *Cancer Res.* 2001, 61, 1659–1665. [PubMed]

65. Zhang, R.; Shao, F.; Wu, X.; Ying, K. Value of quantitative analysis of circulating cell free DNA as a screening tool for lung cancer: A meta-analysis. *Lung Cancer* 2010, 69, 225–231. [CrossRef]

66. Jung, K.; Fleischhacker, M.; Rabien, A. Cell-free DNA in the blood as a solid tumor biomarker-A critical appraisal of the literature. *Clin. Chim. Acta* 2010, 411, 1611–1624. [CrossRef]

67. Sorensen, G.D.; Pribish, D.M.; Valone, F.H.; Memoli, V.A.; Bzik, D.J.; Yao, S.L. Soluble Normal and Mutated DNA Sequences from Single-Copy Genes in Human Blood. *Cancer Epidemiol. Biomark. Prev.* 1994, 3, 67–71.

68. Bailey, P.; Chang, D.K.; Nones, K.; Johns, A.L.; Patch, A.M.; Gingras, M.C.; Miller, D.K.; Christ, A.N.; Bruxner, T.J.C.; Quinn, M.C.; et al. Genomic analyses identify molecular subtypes of pancreatic cancer. *Nature* 2016, 531, 47–52. [CrossRef]

69. Biankin, A.V.; Waddell, N.; Kassahn, K.S.; Gingras, M.C.; Muthuswamy, L.B.; Johns, A.L.; Miller, D.K.; Wilson, P.J.; Patch, A.M.; Wu, J.; et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. *Nature* 2012, 491, 399–405. [CrossRef]

70. Waddell, N.; Pajic, M.; Patch, A.M.; Chang, D.K.; Kassahn, K.S.; Bailey, P.; Johns, A.L.; Miller, D.; Nones, K.; Quek, K.; et al. Whole genomes redefine the mutational landscape of pancreatic cancer. *Nature* 2015, 518, 495–501. [CrossRef] [PubMed]

71. Eser, S.; Schnieke, A.; Schneider, G.; Saur, D. Oncogenic KRAS signalling in pancreatic cancer. *Br. J. Cancer* 2014, 111, 817–822. [CrossRef] [PubMed]

72. Giaccona, M.B.; Ruben, G.C.; Ickzowski, K.A.; Roos, T.B.; Porter, D.M.; Sorensen, G.D. Cell-free DNA in human blood plasma: Length measurements in patients with pancreatic cancer and healthy controls. *Pancreas* 1998, 17, 89–97. [CrossRef] [PubMed]

73. Adamo, P.; Cowley, C.M.; Neal, C.P.; Mistry, V.; Page, K.; Dennison, A.R.; Isherwood, J.; Hastings, R.; Luo, J.L.; Moore, D.A.; et al. Profiling tumour heterogeneity through circulating tumour DNA in patients with pancreatic cancer. *Oncotarget* 2017, 8, 87221–87233. [CrossRef]

74. Park, G.; Park, J.K.; Son, D.S.; Shin, S.H.; Kim, Y.J.; Jeon, H.J.; Lee, J.; Park, W.Y.; Lee, K.H.; Park, D. Utility of targeted deep sequencing for detecting circulating tumor DNA in pancreatic cancer patients. *Sci. Rep.* 2018, 8, 11631. [CrossRef] [PubMed]

75. Pishvaian, M.J.; Bender, R.J.; Matrisian, L.M.; Rahib, L.; Hendifar, A.; Hoos, W.A.; Mikhail, S.; Chung, V.; Picozzi, V.; Heartwell, C.; et al. A pilot study evaluating concordance between blood-based and patient-matched tumor molecular testing within pancreatic cancer patients participating in the Know Your Tumor (KYT) initiative. *Oncotarget* 2017, 8, 83446–83456. [CrossRef] [PubMed]
76. Riviere, P.; Fanta, P.T.; Ikeda, S.; Baumgartner, J.; Heestand, G.M.; Kurzrock, R. The mutational landscape of gastrointestinal malignancies as reflected by circulating tumor DNA. Mol. Cancer 2018, 17, 297–305. [CrossRef]
77. Zill, O.A.; Greene, C.; Sebisanovic, D.; Siew, L.M.; Leng, J.; Vu, M.; Hendifar, A.E.; Wang, Z.; Atreye, C.E.; Kelley, R.K.; et al. Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas. Cancer Discov. 2015, 5, 1040–1048. [CrossRef]
78. Takai, E.; Totoki, Y.; Nakamura, H.; Morizane, C.; Sara, S.; Hama, N.; Suzuki, M.; Furukawa, E.; Kato, M.; Hayashi, H.; et al. Clinical utility of circulating tumor DNA for molecular assessment in pancreatic cancer. Sci. Rep. 2015, 5, 18452. [CrossRef]
79. Vietsch, E.E.; Graham, G.T.; McCutcheon, J.N.; Javaid, A.; Giaccone, G.; Marshall, J.L.; Wellstein, A. Circulating cell-free DNA mutation patterns in early and late stage colon and pancreatic cancer. Cancer Genet. 2017, 218–219, 39–50. [CrossRef]
80. Cohen, J.D.; Javed, A.A.; Thoburn, C.; Wong, F.; Tie, J.; Gibbs, P.; Schmidt, C.M.; Yip-Schneider, M.T.; Allen, P.J.; Schattner, M.; et al. Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers. Proc. Natl. Acad. Sci. USA 2017, 114, 10202–10207. [CrossRef]
81. Le Calvez-Kelm, F.; Foll, M.; Wozniak, M.B.; Delhomme, T.M.; Durand, G.; Chopard, P.; Pertesi, M.; Fabianova, E.; Adamcakova, Z.; Holcatova, I.; et al. KRAS mutations in blood circulating cell-free DNA: A pancreatic cancer case-control study. Oncotarget 2016, 7, 78827–78840. [CrossRef] [PubMed]
82. Berger, A.W.; Schwerdel, D.; Costa, I.G.; Hackert, T.; Strobel, O.; Lam, S.; Barth, T.F.; Schröppel, B.; Meining, A.; Büchler, M.W.; et al. Detection of Hot-Spot Mutations in Circulating Cell-Free DNA from Patients with Intraductal Papillary Mucinous Neoplasms of the Pancreas. Gastroenterology 2016, 151, 267–270. [CrossRef] [PubMed]
83. Cohen, J.D.; Li, L.; Wang, Y.; Thoburn, C.; Afsari, B.; Danilova, L.; Douville, C.; Javed, A.A.; Wong, F.; Mattox, A.; et al. Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science 2018, 359, 926–930. [CrossRef]
84. Berger, A.W.; Schwerdel, D.; Reinacher-Schick, A.; Uh, W.; Algul, H.; Friess, H.; Janssen, K.P.; Konig, A.; Ghadimi, M.; Gallmeier, E.; et al. A Blood-Based Multi Marker Assay Supports the Differential Diagnosis of Early-Stage Pancreatic Cancer. Theranostics 2019, 9, 1280–1287. [CrossRef]
85. Liu, X.; Liu, L.; Ji, Y.; Li, C.; Wei, T.; Yang, X.; Wang, Y.; Gao, Y.; Xu, W.; et al. Enrichment of short mutant cell-free DNA fragments enhanced detection of pancreatic cancer. EBioMedicine 2019, 41, 345–356. [CrossRef]
86. Eissa, M.A.L.; Lerner, L.; Abdellatah, E.; Shankar, N.; Caner, J.K.; Hasan, N.M.; Yaghooibi, V.; Huang, B.; Kerner, Z.; Takaesu, F.; et al. Promoter methylation of ADAMTS1 and BNC1 as potential biomarkers for early detection of pancreatic cancer in blood. Clin. Epigenetics 2019, 11, 59. [CrossRef]
87. Shen, S.Y.; Singhania, R.; Fehringer, G.; Chakravarthy, A.; Roehrl, M.H.A.; Chadwick, D.; Zuzarte, P.C.; Borgida, A.; Wang, T.T.; Li, T.; et al. Sensitive tumour detection and classification using plasma cell-free DNA methylomes. Nature 2018, 563, 579–583. [CrossRef]
88. Kim, M.K.; Woo, S.M.; Park, B.; Yoon, K.A.; Kim, Y.H.; Joo, J.; Lee, W.J.; Han, S.S.; Park, S.J.; Kong, S.Y. Prognostic Implications of Multiplex Detection of KRAS Mutations in Cell-Free DNA from Patients with Pancreatic Ductal Adenocarcinoma. Clin. Chem. 2018, 64, 726–734. [CrossRef]
89. Strijker, M.; Soer, E.C.; de Pastena, M.; Creemers, A.; Balduzzi, A.; Beagan, J.J.; Busch, O.R.; van Delden, O.M.; Halfwerk, H.; van Hooft, J.E.; et al. Circulating tumor DNA quantity is related to tumor volume and both predict survival in metastatic pancreatic ductal adenocarcinoma. Int. J. Cancer 2020, 146, 1445–1456. [CrossRef]
90. Tjensvoll, K.; Lapin, M.; Buhl, T.; Oltedal, S.; Steen-Ottosen Berry, K.; Gilje, B.; Søreide, J.A.; Javle, M.; Nordgård, O.; Smaaland, R. Clinical relevance of circulating KRAS mutated DNA in plasma from patients with advanced pancreatic cancer. Mol. Oncol. 2016, 10, 635–643. [CrossRef]
91. Earl, J.; Garcia-Nieto, S.; Martinez-Avila, J.C.; Montans, J.; Sanjuanbenito, A.; Rodriguez-Garrote, M.; Lisa, E.; Mendia, E.; Lobo, E.; Malats, N.; et al. Circulating tumor cells (Ctc) and kras mutant circulating free Dna (cfDNA) detection in peripheral blood as biomarkers in patients diagnosed with exocrine pancreatic cancer. BMC Cancer 2015, 15, 797. [CrossRef]
92. Hadano, N.; Murakami, Y.; Uemura, K.; Hashimoto, Y.; Kondo, N.; Nakagawa, N.; Sueda, T.; Hiyama, E. Prognostic value of circulating tumour DNA in patients undergoing curative resection for pancreatic cancer. Br. J. Cancer 2016, 115, 59–65. [CrossRef]
93. Bernard, V.; Kim, D.U.; San Lucas, F.A.; Castillo, J.; Allenson, K.; Mulu, F.C.; Stephens, B.M.; Huang, J.; Semaan, A.; Guerrero, P.A.; et al. Circulating Nucleic Acids Are Associated with Outcomes of Patients with Pancreatic Cancer. Gastroenterology 2019, 156, 108–118. [CrossRef] [PubMed]

94. Cheng, H.; Liu, C.; Jiang, J.; Luo, G.; Lu, Y.; Jin, K.; Guo, M.; Zhang, Z.; Xu, J.; Liu, L.; et al. Analysis of ctDNA to predict prognosis and monitor treatment responses in metastatic pancreatic cancer patients. Int. J. Cancer 2017, 140, 2344–2350. [CrossRef] [PubMed]

95. Del Re, M.; Vivaldi, C.; Roffi, E.; Vasile, E.; Miccoli, M.; Caparello, C.; D’Arienzo, P.D.; Fornaro, L.; Falcone, A.; Danesi, R. Early changes in plasma DNA levels of mutant KRAS as a sensitive marker of response to chemotherapy in pancreatic cancer. Sci. Rep. 2017, 7, 8. [CrossRef] [PubMed]

96. Kruger, S.; Heinemann, V.; Ross, C.; Diehl, F.; Nagel, D.; Ormanns, S.; Liebmamn, S.; Prinz-Bravin, I.; Westphalen, C.B.; Haas, M.; et al. Repeated mut KRAS ctDNA measurements represent a novel and promising tool for early response prediction and therapy monitoring in advanced pancreatic cancer. Ann. Oncol. 2018, 29, 2348–2355. [CrossRef] [PubMed]

97. Mohan, S.; Ayub, M.; Rothwell, D.G.; Gulati, S.; Kilerci, B.; Hollebecque, A.; Sun Leong, H.; Smith, N.K.; Sahoo, S.; Descamps, T.; et al. Analysis of circulating cell-free DNA identifies KRAS copy number gain and mutation as a novel prognostic marker in Pancreatic cancer. Sci. Rep. 2019, 9, 11610. [CrossRef]

98. Nakano, Y.; Kitago, M.; Matsuda, S.; Nakamura, Y.; Fujita, Y.; Inai, S.; Shinoda, M.; Yagi, H.; Abe, Y.; Hibi, T.; et al. KRAS mutations in cell-free DNA from preoperative and postoperative sera as a pancreatic cancer marker: A retrospective study. Br. J. Cancer 2018, 118, 662–669. [CrossRef]

99. Petersen, G.M.; Wang, L. Leukocyte DNA methylation signature differentiates pancreatic cancer patients from healthy controls. PLoS ONE 2011, 6, e18223. [CrossRef]
Cancers 2020, 12, 3234

111. Tumas, J.; Baskirova, I.; Petrenas, T.; Norkuniene, J.; Strupas, K.; Sileikis, A. Towards a personalized approach in pancreatic cancer diagnostics through plasma amino acid analysis. Anticancer Res. 2019, 39, 2035-2042. [CrossRef]

112. Battini, S.; Faitot, F.; Imperiale, A.; Cicek, A.E.; Heimburger, C.; Bachellier, P.; Namer, I.J. Applications of metabolomics in cancer studies. In Advances in Experimental Medicine and Biology; Springer: New York, NY, USA, 2017; Volume 965, pp. 209–234.

113. Riquelme, E.; Maitra, A.; McAllister, F. Immunotherapy for pancreatic cancer: More than just a gut feeling. Cancer Res. 2009, 69, 7030–7040. [CrossRef] [PubMed]

114. Thordarson, T.D.; Hruban, R.H.; Gishlick, A.; Severson, K.; El-Serag, B.H.; El-Serag, H.B. The Activated Stroma Index Is a Novel and Independent Prognostic Marker in Pancreatic Cancer. Clin. Gastroenterol. Hepatol. 2016, 14, 1258-1264. [CrossRef] [PubMed]

115. Tumas, J.; Baskirova, I.; Petrenas, T.; Norkuniene, J.; Strupas, K.; Sileikis, A. Towards a personalized approach in pancreatic cancer diagnostics through plasma amino acid analysis. Anticancer Res. 2019, 39, 2035-2042. [CrossRef]

116. DiGangi, I.M.; Mazza, T.; Fontana, A.; Copetti, M.; Fusili, C.; Ippolito, A.; Mattivi, F.; Latiano, A.; Andriulli, A.; Vrhovsek, U.; et al. Metabolomic profile in pancreatic cancer patients: A consensus-based approach to identify highly discriminating metabolites. Oncotarget 2016, 7, 5815–5829. [CrossRef]

117. Moore, H.B.; Culp-Hill, R.; Reisz, J.A.; Lawson, P.J.; Sauaia, A.; Schulick, R.D.; Del Chiaro, M.; Nydam, T.L.; Moore, E.E.; Hansen, K.C.; et al. The metabolic time line of pancreatic cancer: Opportunities to improve early detection of adenocarcinoma. Am. J. Surg. 2019, 218, 1206–1212. [CrossRef]

118. Whatcott, C.J.; Han, H.; Von Hoff, D.D. Orchestrating the Tumor Microenvironment to Improve Survival for Patients with Pancreatic Cancer. Cancer J. 2015, 21, 299–306. [CrossRef] [PubMed]

119. Phua, L.C.; Koh, S.; Tai, D.W.M.; Leow, W.Q.; Alka, I.; Knudsen, E.S.; Vail, P.; Balaji, U.; Ngo, H.; Botros, I.W.; Makarov, V.; Riaz, N.; Balachandran, V.; Leach, S.; Thompson, D.M.; et al. Metabolomic approaches in pancreatic adenocarcinoma: Tumor metabolism profiling predicts clinical outcome of patients. BMC Med. 2017, 15, 56. [CrossRef] [PubMed]

120. Feldmann, K.; Maurer, C.; Peschke, K.; Teller, S.; Schuck, K.; Steiger, K.; Engleitner, T.; Öllinger, R.; Nomura, A.; Wirges, N.; et al. Mesenchymal plasticity regulated by Prrx1 drives aggressive pancreatic cancer biology. Gut 2018, 67, 1477–1490. [CrossRef] [PubMed]

121. Silva, R.; Kalemkerian, P.G.; Muller, M.; Thompson, D.M.; et al. Stratification of pancreatic ductal adenocarcinoma: Combinatorial genetic, stromal, and immunologic markers. Clin. Cancer Res. 2017, 23, 4429–4440. [CrossRef]
131. Moffitt, R.A.; Marayati, R.; Flate, E.L.; Volmar, K.E.; Loeza, S.G.H.; Hoadley, K.A.; Rashid, N.U.; Williams, L.A.; Eaton, S.C.; Chung, A.H.; et al. Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma. *Nat. Genet.* 2015, 47, 1168–1178. [CrossRef]

132. Ramu, I.; Buchholz, S.M.; Patzak, M.S.; Goetze, R.G.; Singh, S.K.; Richards, F.M.; Jodrell, D.J.; Sipos, B.; Ströbel, P.; Ellenrieder, V.; et al. SPARC dependent collagen deposition and gemcitabine delivery in a genetically engineered mouse model of pancreatic cancer. *EBioMedicine* 2019, 48, 161–168. [CrossRef]

133. Gorchs, L.; Ahmed, S.; Mayer, C.; Knauf, A.; Fernández Moro, C.; Svensson, M.; Heuchel, R.; Rangelova, E.; Bergman, P.; Kape, H. The vitamin D analogue calcipotriol promotes an anti-tumorigenic phenotype of human pancreatic CAFs but reduces T cell mediated immunity. *Sci. Rep.* 2020, 10, 17444. [CrossRef]

134. Olive, K.P.; Jacobetz, M.A.; Davidson, C.J.; Gopinathan, A.; McIntyre, D.; Honess, D.; Madhu, B.; Özdemir, B.C.; Pentcheva-Hoang, T.; Carstens, J.L.; Zheng, X.; Wu, C.C.; Simpson, T.R.; Laklai, H.; Sugimoto, H.; Kahlert, C.; Novitskiy, S.V.; et al. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. *Cancer Cell* 2014, 25, 719–734. [CrossRef] [PubMed]

135. Özdemir, B.C.; Bentcheva-Hoang, T.; Carstens, J.L.; Zheng, X.; Wu, C.C.; Simpson, T.R.; Laklai, H.; Sugimoto, H.; Kahlert, C.; Novitskiy, S.V.; et al. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. *Cancer Cell* 2014, 25, 719–734. [CrossRef] [PubMed]

136. Ramu, I.; Buchholz, S.M.; Patzak, M.S.; Goetze, R.G.; Singh, S.K.; Richards, F.M.; Jodrell, D.J.; Sipos, B.; Ströbel, P.; Ellenrieder, V.; et al. SPARC dependent collagen deposition and gemcitabine delivery in a genetically engineered mouse model of pancreatic cancer. *EBioMedicine* 2019, 48, 161–168. [CrossRef]

137. Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: The next generation. *Cell* 2011, 144, 646–674. [CrossRef]

138. Ferrone, C.; Dranoff, G. Dual roles for immunity in gastrointestinal cancers. *J. Clin. Oncol.* 2010, 28, 4045–4051. [CrossRef]

139. Dunn, G.P.; Old, L.J.; Schreiber, R.D. The three Es of cancer immunoediting. *Annu. Rev. Immunol.* 2004, 22, 329–360. [CrossRef]

140. Tewari, N.; Zaitoun, A.M.; Arora, A.; Madhusudan, S.; Lobo, D.N. The presence of tumour-associated lymphocytes confers a good prognosis in pancreatic ductal adenocarcinoma. *J. Exp. Med.* 2017, 214, 579–596. [CrossRef]

141. Elyada, E.; Bolisetty, M.; Laise, P.; Flynn, W.F.; Courtois, E.T.; Burkhart, R.A.; Teinor, J.A.; Belleau, P.; Biffi, G.; Lucito, M.S.; et al. Cross-species single-cell analysis of pancreatic ductal adenocarcinoma reveals antigen-presenting cancer-associated fibroblasts. *Cancer Discov.* 2019, 9, 1102–1123. [CrossRef]

142. Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: The next generation. *Cell* 2011, 144, 646–674. [CrossRef]

143. Dunn, G.P.; Old, L.J.; Schreiber, R.D. The three Es of cancer immunoediting. *Annu. Rev. Immunol.* 2004, 22, 329–360. [CrossRef]

144. Tewari, N.; Zaitoun, A.M.; Arora, A.; Madhusudan, S.; Lobo, D.N. The presence of tumour-associated lymphocytes confers a good prognosis in pancreatic ductal adenocarcinoma. *J. Exp. Med.* 2017, 214, 579–596. [CrossRef]

145. Biffi, G.; Lucito, M.S.; et al. Cross-species single-cell analysis of pancreatic ductal adenocarcinoma reveals antigen-presenting cancer-associated fibroblasts. *Cancer Discov.* 2019, 9, 1102–1123. [CrossRef]

146. Öhlund, D.; Handly-Santana, A.; Biffi, G.; Elyada, E.; Almeida, A.S.; Ponz-Sarvise, M.; Corbo, V.; Oni, T.E.; Hearn, S.A.; Lee, E.J.; et al. Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. *J. Exp. Med.* 2017, 214, 579–596. [CrossRef]

147. Ferrone, C.; Dranoff, G. Dual roles for immunity in gastrointestinal cancers. *J. Clin. Oncol.* 2010, 28, 4045–4051. [CrossRef]

148. Royal, R.E.; Levy, C.; Turner, K.; Mathur, A.; Hughes, M.; Kammula, U.S.; Sherry, R.M.; Topalian, S.L.; Yang, J.C.; Lowy, I.; et al. Phase 2 trial of single agent ipilimumab (Anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. *J. Immunother.* 2010, 33, 828–833. [CrossRef] [PubMed]
149. Brentjens, R.J.; Davila, M.L.; Riviere, I.; Park, J.; Wang, X.; Cowell, L.G.; Bartido, S.; Stefanski, J.; Taylor, C.; Olszewska, M.; et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. *Sci. Transl. Med.* 2013, 5, 177ra38. [CrossRef]

150. Kochenderfer, J.N.; Dudley, M.E.; Feldman, S.A.; Wilson, W.H.; Spaner, D.E.; Maric, I.; Stetler-Stevenson, M.; Phan, G.Q.; Hughes, M.S.; Sherry, R.M.; et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. *Blood* 2012, 119, 2709–2720. [CrossRef]

151. Grupp, S.A.; Kalos, M.; Barrett, D.; Aplenc, R.; Porter, D.L.; Rheingold, S.R.; Teachey, D.T.; Chew, A.; Hauck, B.; Wright, J.F.; et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. *N. Engl. J. Med.* 2013, 368, 1509–1518. [CrossRef]

152. Wedén, S.; Klemm, M.; Gladhaug, I.P.; Måller, M.; Eriksen, J.A.; Gaudernack, G.; Buanes, T. Long-term follow-up of patients with resected pancreatic cancer following vaccination against mutant K-ras. *Int. J. Cancer* 2011, 128, 1120–1128. [CrossRef] [PubMed]

153. Gjertsen, M.K.; Buanes, T.; Rosseland, A.R.; Bakka, A.; Gladhaug, I.; Sreide, O.; Eriksen, J.A. Intradermal ras peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant: Clinical and immunological responses in patients with pancreatic adenocarcinoma. *Int. J. Cancer* 2001, 92, 441–450. [CrossRef] [PubMed]

154. Eric, L.; Yeo, C.J.; Lillemoe, K.D.; Biedrzycki, B.; Laheru, D.; Schepers, K.; Sauter, P.R.; Goemann, M.; Coleman, J.; Grochow, L.; Donehower, R.C.; et al. Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: A phase I trial of safety and immune activation. *J. Clin. Oncol.* 2001, 19, 145–156. [CrossRef]

155. Eric, L.; Yeo, C.J.; Lillemoe, K.D.; Biedrzycki, B.; Kobbri, B.; Herman, J.; Sugar, E.; Plantadosi, S.; Cameron, J.L.; Solt, S.; et al. A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma: A phase II trial of safety, efficacy, and immune activation. *Ann. Surg.* 2011, 253, 328–335. [CrossRef] [PubMed]

156. Le, D.T.; Wang-Gillam, A.; Picozzi, V.; Greten, T.F.; Crocenzi, T.; Springer, G.; Morse, M.; Zeh, H.; Cohen, D.; Fine, R.L.; et al. Safety and survival with GVAX pancreas prime and Listeria monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. *J. Clin. Oncol.* 2015, 33, 1325–1333. [CrossRef]

157. Groeneveldt, C.; Kinderman, P.; van den Wollenberg, D.J.M.; van den Oever, R.L.; Middelburg, J.; Mustafa, D.A.M.; Hoeben, R.C.; van der Burg, S.H.; van Hall, T.; van Montfoort, N. Preconditioning of the tumor microenvironment with oncolytic reovirus converts CD3-bispecific antibody treatment into effective immunotherapy. *J. Immunother. Cancer* 2020, 8, e001911. [CrossRef]

158. Le, D.T.; Durham, J.N.; Smith, K.N.; Wang, H.; Bartlett, B.R.; Aulakh, L.K.; Lu, S.; Kemberling, H.; Wilt, C.; Lubber, B.S.; et al.Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. *Science* 2017, 357, 409–413. [CrossRef]

159. Picardo, S.L.; Coburn, B.; Hansen, A.R. The microbiome and cancer for clinicians. *Crit. Rev. Oncol. Hematol.* 2019, 141, 1–12. [CrossRef]

160. Topalian, S.L.; Drake, C.G.; Pardoll, D.M. Immune checkpoint blockade: A common denominator approach to cancer therapy. *Cancer Cell* 2015, 27, 450–461. [CrossRef]

161. Tumeh, P.C.; Harvie, C.L.; Yearley, J.H.; Shintaku, I.P.; Taylor, E.J.M.; Robert, L.; Chmielowski, B.; Spasic, M.; Henry, G.; Ciobanu, V.; et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. *Nature* 2015, 515, 568–571. [CrossRef]

162. Mustafa, D.A.M.; Hoeben, R.C.; van der Burg, S.H.; van Hall, T.; van Montfoort, N. Preconditioning of the tumor vaccine for pancreatic adenocarcinoma: A phase II trial of safety, efficacy, and immune activation. *Int. J. Cancer* 2015, 6, 7209–7220. [CrossRef]

163. Mitsuhashi, K.; Nosho, K.; Takahashi, A.; Matsunaga, Y.; Ito, M.; Kurilshikov, H.; Kanno, S.; Igashira, H.; Naito, T.; Adachi, Y.; et al. Association of Fusobacterium species in pancreatic cancer tissues with molecular features and prognosis. *Oncotarget* 2015, 6, 7209–7220. [CrossRef]

164. Fan, X.; Alekseyenko, A.V.; Wu, J.; Peters, B.A.; Jacobs, E.J.; Gapstur, S.M.; Purdue, M.P.; Abnet, C.C.; Stolzenberg-Solomon, R.; Miller, G.; et al. Human oral microbiome and prospective risk for pancreatic cancer: A population-based nested case-control study. *Gut* 2018, 67, 120–127. [CrossRef]
165. Michaud, D.S.; Izard, J.; Wilhelm-Benartzi, C.S.; You, D.H.; Grote, V.A.; Tjønneland, A.; Dahm, C.C.; Overvad, K.; Jenab, M.; Fedirko, V.; et al. Plasma antibodies to oral bacteria and risk of pancreatic cancer in a large European prospective cohort study. Gut 2013, 62, 1764–1770. [CrossRef]

166. Matson, V.; Fessler, J.; Bao, R.; Chongsuwat, T.; Zha, Y.; Alegre, M.L.; Luke, J.J.; Gajewski, T.F. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science 2018, 359, 104–108. [CrossRef] [PubMed]

167. Gopalakrishnan, V.; Spencer, C.N.; Nezi, L.; Reuben, A.; Andrews, M.C.; Karpinets, T.V.; Prieto, P.A.; Vicente, D.; Hoffman, K.; Wei, S.C.; et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 2018, 359, 97–103. [CrossRef] [PubMed]

168. Routy, B.; Le Chatelier, E.; Derosa, L.; Duong, C.P.M.; Alou, M.T.; Daillère, R.; Fluckiger, A.; Messaoudene, M.; Rauber, C.; Roberti, M.P.; et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science 2018, 359, 91–97. [CrossRef] [PubMed]

169. Riquelme, E.; Zhang, Y.; Zhang, L.; Montiel, M.; Zoltan, M.; Dong, W.; Quesada, P.; Sahin, I.; Chandra, V.; San Lucas, A.; et al. Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes. Cell 2019, 178, 795–806. [CrossRef]

170. Mendez, R.; Kesh, K.; Arora, N.; Di Martino, L.; McAllister, F.; Merchant, N.; Banerjee, S.; Banerjee, S. Microbial dysbiosis and polyamine metabolism as predictive markers for early detection of pancreatic cancer. Carcinogenesis 2020, 41, 561–570. [CrossRef]

Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).